Title: The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Author: Robert Roskoski Jr.

PII: S1043-6618(18)30599-1
DOI: https://doi.org/10.1016/j.phrs.2018.04.020
Reference: YPHRS 3886

To appear in: *Pharmacological Research*

Received date: 23-4-2018
Accepted date: 23-4-2018

Please cite this article as: Roskoski Robert.The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.*Pharmacological Research* https://doi.org/10.1016/j.phrs.2018.04.020

The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Robert Roskoski Jr.

Blue Ridge Institute for Medical Research

3754 Brevard Road, Suite 116, Box 19

Horse Shoe, North Carolina 28742-8814, United States

Phone: 1-828-891-5637

Fax: 1-828-890-8130

E-mail address: rrj@brimr.org

Keywords;

Chemical compounds studied in this article: Axitinib: (PubMED CID: 6450551); Cabozantinib (PubMED CID: 25102847); Dasatinib: (PubMED CID: 3062316); Imatinib: (PubMED CID: 5291); Lenvatinib: (PubMED CID: 9823820); Midostaurin: (PubMED CID; 9829523); Ponatinib: (PubMed CID: 24826799); Regorafenib: (PubMed CID: 11167602); Sorafenib: (PubMed CID: 216239); Sunitinib: (PubMed CID: 5329102)

Abbreviations: AS, activation segment; CS or C-spine, catalytic spine; CL, catalytic loop; CTT, carboxyterminal tail; D1, immunoglobulin-like domain-1; EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumors; GK, gatekeeper; GRL, Gly-rich loop; KD, kinase domain; KID, kinase insert domain; JM, juxtamembrane; PDGFR, platelet-derived growth factor receptor; PKA, protein kinase A; Ph^+, Philadelphia chromosome positive; PKC, protein kinase C; pY or pTyr, phosphotyrosine; RS or R-spine, regulatory spine; Sh2, shell residue 2; TM, transmembrane, VEGFR, vascular endothelial growth factor receptor.

Graphical Abstract